A Texas federal judge kept the abortion pill lawsuit alive but froze it until the Food and Drug Administration finishes its safety review, pushing any ruling past key elections.
Story Snapshot
- A judge paused the Florida–Texas case but refused to dismiss it, keeping the challenge active.
- The states cleared an early hurdle on standing tied to Medicaid costs from complications.
- The suit targets the original 2000 approval of mifepristone and later mail access rules.
- The Supreme Court’s 2024 ruling left safety merits unresolved by deciding on standing.
What the Court Did and Why It Matters
Chief United States District Judge Reed O’Connor rejected drugmakers’ motions to dismiss and paused the case while the Food and Drug Administration completes an ongoing safety review of mifepristone. The order delays any merits ruling until December 1 or until the agency finishes its review, whichever comes first. The timing means voters will not see a court decision before midterms. The case remains active, so both sides must prepare for full litigation once the pause lifts.
Florida and Texas argued that state Medicaid programs pay for care linked to abortion pill complications. Bloomberg Law reported the judge said the states alleged facts that connect real costs to out-of-state use of the drug, which supports standing at this stage. That finding lets the states pursue their claims later. It also signals that cost-based injuries could open the courthouse door where other theories have failed.
What the Lawsuit Challenges
The states challenge both the Food and Drug Administration’s original 2000 approval of mifepristone and later rules that widened access, including a 2023 policy that allows dispensing by mail. That strategy gives them more than one target. If courts view the original approval as time-barred, they could still scrutinize newer rules. A prior district ruling in 2023 sought to stay approval, showing some judges have questioned the agency’s path before, even though higher courts later narrowed that case.
The Supreme Court’s 2024 decision did not decide whether the drug is safe or lawfully approved. The justices said the earlier physician challengers lacked standing, and that ended the case on procedure, not on the merits. Defenders of the Food and Drug Administration cite that ruling to argue courts should avoid second-guessing the agency. Challengers point out the safety and approval questions were never answered by the high court.
What the Food and Drug Administration Says About Safety
The Food and Drug Administration states that its periodic reviews of post-marketing data have not found new safety concerns for use of mifepristone through 70 days of pregnancy. A 2023 Center for Drug Evaluation and Research record also reported no new safety concerns in recent review materials. In 2021, the agency said data supported changes to the Risk Evaluation and Mitigation Strategy to reduce burdens while keeping benefits greater than risks. Those positions will weigh heavily during the agency’s current review.
LADIES, RED ALERT.
Federal judge delays mifepristone lawsuit until after midterms granted a request by the Department of Justice to delay the lawsuit filed by the attorneys general of Texas and Florida until either Dec. 1 or when the FDA finishes REVIEWhttps://t.co/j5YIZR4eMO
— Nancy Willing (@NancyWilling1) September 1, 2026
Reuters has reported similar pauses in related cases as judges wait for the Food and Drug Administration’s reassessment, with one judge calling agency review “in the public interest” over “government by lawsuit”. Supporters say this protects science-based review from political whiplash. Critics see a stall that keeps a hot issue quiet before voters. Either way, the pause shifts power back to the agency for now, while courts hold off on a sweeping ruling.
What to Watch Next
Watch for the scope and speed of the Food and Drug Administration’s safety review. If the agency releases new data, it could change the legal fight by confirming current rules or proposing changes. Also watch whether the court narrows claims once litigation resumes. The states’ cost evidence will face deeper tests, and discovery requests may seek internal agency records. For voters on both left and right, the delay underscores a system that often moves slower than the problems people want solved.
Sources:
lifesitenews.com, usnews.com, news.bloomberglaw.com, commondreams.org, law.utexas.edu, en.wikipedia.org, pbs.org, supremecourt.gov, npr.org
